Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05862545
Other study ID # D5980R00076
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date June 1, 2023
Est. completion date July 28, 2025

Study information

Verified date June 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.


Description:

The therapeutic goal of chronic obstructive pulmonary disease (COPD) management is mainly reduction of symptoms and severity of exacerbations.Triple therapy (the combination of an ICS, a LABA and a LAMA) in a single fixed-dose combination is a valuable development in the treatment of COPD. On top of treatment adherence enhancement [Gaduzo et al., 2019], trials showed triple therapy improving lung function, Patients-Reported Outcomes (PROs), health-related quality of life, as well as lowering exacerbations and hospitalization rate compared to dual or mono-therapy [Bourbeau et al., 2021; Zheng et al, 2018]. Budesonide/glycopyrrolate/formoterol fumarate, hereafter BGF, is a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The availability of single-inhaler triple therapies in routine care may improve symptoms control, reduce exacerbation rate and COPD-related healthcare costs, thus leading to an improvement in patient health status and quality of life. However, real-world studies focusing on PROs are still limited. The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 250
Est. completion date July 28, 2025
Est. primary completion date July 28, 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 120 Years
Eligibility Inclusion Criteria: 1. Male or female, aged >= 40; 2. Physician-diagnosed COPD; 3. Signed written informed and privacy consent prior to study participation; 4. Patients starting treatment with BGF as prescribed according to the label, local market reimbursement criteria, and AIFA Nota 99; 5. Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol. Exclusion Criteria: 1. COPD due to documented a-1 antitrypsin deficiency; 2. Patients with controlled COPD treated with triple fixed-dose combination in 12 months prior to screening visits; 3. Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment; 4. Pregnancy or lactation period; 5. Participation in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in any interventional, observational or clinical trial in the last 30 days prior to enrolment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BGF (budesonide/glycopyrrolate/formoterol fumarate)
BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.

Locations

Country Name City State
Italy Research Site Acquaviva delle Fonti
Italy Research Site Alessandria
Italy Research Site Ancona
Italy Research Site Avellino
Italy Research Site Brescia
Italy Research Site Brindisi
Italy Research Site Busto Arsizio (Varese)
Italy Research Site Catania
Italy Research Site Catanzaro
Italy Research Site Cittadella (Padova)
Italy Research Site Firenze
Italy Research Site Foggia
Italy Research Site Lecce
Italy Research Site Napoli
Italy Research Site Passirana (Milano)
Italy Research Site Pavia
Italy Research Site Roma
Italy Research Site Torino
Italy Research Site Treviso
Italy Research Site Verona

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG. Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021 Mar 1;16:499-517. doi: 10.2147/COPD.S291967. eCollection 2021. — View Citation

Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019 Feb 13;14:391-401. doi: 10.2147/COPD.S173901. eCollection 2019. — View Citation

Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, Wu J, Yao W. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018 Nov 6;363:k4388. doi: 10.1136/bmj.k4388. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Relation between patient CAT score (dependent variable of interest) and patient baseline characteristics To describe the relation of baseline characteristics and the impact of COPD on patients' life during the observation period of treatment with BGF, administered as per routine clinical practice 52 weeks
Other Baseline variables associated with exacerbations To describe the relation of baseline characteristics and occurrence of COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. The analysis will be performed in steps. Firstly, univariate Poisson regression models for the estimated impact on exacerbations occurrence during the observation period will be estimated independently considering the baseline variables (age, sex, BMI, smoking status, eosinophil count in peripheral blood, COPD phenotype and years from diagnosis, number of previous MACEs, number of moderate - severe COPD exacerbations in the year before BGF treatment start, and OCS use in the year before BGF treatment start). Then a multivariate Poisson regression model will be estimated including relevant variables (i.e. with a significant estimated coefficient), as evaluated through the single univariate regression models and the number of exacerbations during follow up 52 weeks
Other Occurrence of Major Cardiovascular Events (MACE) To describe the occurrence of Major Cardiovascular Events (MACE) during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to first MACE (cardiovascular death, myocardial infarction, or ischemic stroke) occurred during the BGF treatment observation period will be computed by means of a Kaplan-Meier analysis. In case patients do not experience a MACE, they will be considered as censored observations and time until the end of their observation will be calculated. In addition, the count of MACE and the absolute and relative frequency of patients with a MACE will be calculated during the BGF treatment observation period. 52 weeks
Other Mortality rate To assess the mortality during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to death occurred during the observation period after BGF treatment start will be computed by means of a Kaplan-Meier analysis. The count of mortality events during the observation period will be reported too. 52 weeks
Primary COPD Assessment Test (CAT) score The change from baseline in COPD Assessment Test (CAT) score after 12 weeks treatment will be analysed using the within person difference between baseline and 12 weeks. Descriptive statistics (mean, median, standard deviation, interquartile range, minimum and maximum) will be provided. The mean change from baseline will be presented along with the 95% CI baseline, 12 weeks after treatment start
Secondary Baseline features To describe the baseline features of patients starting BGF treatment in a real-world setting, in terms of demographics and clinical characteristics, COPD treatment paths and healthcare resource utilization in the previous year. Baseline
Secondary Impact of COPD on patients' life based on CAT To describe the impact of COPD on patients' life, and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. COPD Assessment Test (CAT) questionnaire at baseline and after 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, CAT questionnaire will also be collected at the end of observation. baseline, 26 and 52 weeks
Secondary Patients' satisfaction to BGF 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, TSQM-9 questionnaire will also be collected at the end of observation. baseline, 26 and 52 weeks
Secondary Patient dyspnoea based on Modified Medical Research Council Dyspnoea Scale (mMRC) To describe patient dyspnoea and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. Modified Medical Research Council Dyspnoea Scale (mMRC) questionnaire at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, mMRC questionnaire will also be collected at the end of observation. Baseline, 26 and 52 weeks
Secondary Eosinophil count To describe the eosinophil count during the observation period of treatment with BGF, administered as per routine clinical practice. Eosinophil count in peripheral blood at baseline visit, and 26- and 52-week visits, which will occur after BGF treatment start, where available. baseline, 26 and 52 weeks
Secondary Responder Rate based on CAT To describe the Responder Rate based on the CAT after 12 weeks of initiating treatment with BGF as per routine clinical practice. Number and rate of responders of the CAT [MID=2] after 12 weeks of BGF treatment. 12 weeks
Secondary Overall change in health status based on Patient Global Impression of Severity (PGIS) questionnaire To assess patient-reported overall change in health status since the start of study treatment and overall global impression of severity during the observation period of treatment with BGF as per routine clinical practice. Single-item patient severity of COPD symptoms using PGIS at baseline, 12, 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, PGIS questionnaire will also be collected at the end of observation. Baseline, 12, 26 and 52 weeks
Secondary Exacerbation rate To describe the occurrence of moderate - severe COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. Number of moderate - severe COPD exacerbations, occurred during the BGF observation period and Annualized rate of moderate - severe COPD exacerbations during the BGF treatment observation period 52 weeks
Secondary Lung function Describe Lung function parameters as measured at baseline and 52-week visit, available as per routine clinical practice. 52 weeks
Secondary OCS use To describe the Oral Corticosteroids (OCS) use during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. OCS use during the observation period after BGF treatment start, and OCS use in the 52 weeks before BGF treatment start. 52 weeks
Secondary HCRU To describe the healthcare resource utilization related to COPD during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. The number of GP/specialist visits, ER admissions, and hospitalizations (along with duration) related to COPD during the BGF observation period and the 52 weeks prior baseline will be described. The annualised rate of utilization per each type will be calculated. 52 weeks
Secondary Safety (frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period) To describe safety profile of BGF during the observation period Absolute and relative frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period will be calculated. Moreover, the count of such events will be provided. Descriptive statistics will also be provided for severity, seriousness criteria (where applicable), relation grade with BGF, action taken and outcome. 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy